XJPX
3386
Market cap45mUSD
Jul 10, Last price
1,255.00JPY
1D
-0.24%
1Q
-1.34%
Jan 2017
0.00%
IPO
-53.35%
Name
Cosmo Bio Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Cosmo Bio Company, Limited is a key player in the life science research sector, involved in the global import, export, manufacturing, marketing, and distribution of essential biotools. Their extensive product line includes biochemical reagents, specialized kits, scientific instruments, analytical software, and diagnostic products. Among their research reagents, they offer a wide spectrum such as antibodies, antigens, bioactive substances, enzymes, peptides, amino acids, various chemicals, carbohydrates, lipids, and components derived from viruses and bacteria. They also provide crucial detection reagents, cell and tissue culture systems, and gene analysis solutions. In terms of instrumentation, Cosmo Bio supplies electrophoresis apparatuses, cell culture labware, gene manipulation systems, and data analysis software. Beyond products, the company delivers valuable services like drug discovery support, custom research, and clinical diagnostics. A significant part of their operation involves the development and manufacturing of proprietary cell and cell culture products. This includes a range of specialized cells such as adipose tissue, bone, cartilage, tooth, pancreas, liver function, cardiovascular, immune, and mesenchymal stem cells, in addition to feeder cells, tumor cell lines, coating reagents, and macrophage-related products. They also produce various assay kits for measurement, staining, detection, and purification. Furthermore, they offer specialized biotechnology research equipment, including constant-temperature transport containers, aluminum block heat insulation devices, and dew condensation prevention glass plates, alongside consigned services for custom peptide synthesis and antibody production. Serving a diverse clientele of laboratories, research institutes, and life science education and testing organizations, Cosmo Bio distributes its products through its own outlets in Japan and an international network of sales agents. The company was founded in Tokyo, Japan, in 1978, where its headquarters remain.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||